SECOND GENERATION FATTY ACID COMPOSITIONS, FORMULATIONS, AND METHODS OF USE AND SYNTHESIS THEREOF

摘要

An orally administered fatty acid composition for the treatment of cardiovascular diseases, and a method of treating same, are provided. The composition may include at least one omega-3 fatty acid amide, and/or at least one omega-3 fatty acid plus ethanolamine, and at least one tocotrienol. The composition may include 5Z,8Z,l lZ,14Z,17Z-eicosapentaenoic ethanolamide (EPA ethanolamide), 4Z,7Z,10Z,13Z,16Z,19Z-docosahexaenoic ethanolamide (DHA ethanolamide), and at least one tocotrienol. The EPA ethanolamide and the DHA ethanolamide are preferably each substantially in a range of 100 - 900 mg per dosage form. The at least one tocotrienol is substantially in a range of 10 - 500 mg per dosage form. The at least one tocotrienol includes at least one of α-tocotrienol, β- tocotrienol, γ-tocotrienol, or δ-tocotrienol and is preferably substantially tocopherol- free. The composition may take the form of a medical food or a pharmaceutical preparation. A preferred formulation of the composition includes approximately 525 mg EPA ethanolamide, approximately 315 mg DHA ethanolamide, and approximately 50 mg δ-tocotrienol. The EPA and DHA ethanolamides may be synthesized from fatty acid triglycerides.